209 related articles for article (PubMed ID: 37772587)
1. Clinical Outcomes With Lenvatinib in Patients Previously Treated With Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma.
Muto H; Kuzuya T; Kawabe N; Ohno E; Funasaka K; Nagasaka M; Nakagawa Y; Miyahara R; Shibata T; Hashimoto S; Katano Y; Hirooka Y
Anticancer Res; 2023 Oct; 43(10):4673-4682. PubMed ID: 37772587
[TBL] [Abstract][Full Text] [Related]
2. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Shibata H; Aoki T; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M;
Cancer Med; 2023 Jan; 12(1):325-334. PubMed ID: 35666040
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment eosinophil count predicts response to atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma.
Toshida K; Itoh S; Yoshiya S; Nagao Y; Tomino T; Izumi T; Iseda N; Toshima T; Ninomiya M; Yoshizumi T
J Gastroenterol Hepatol; 2024 Mar; 39(3):576-586. PubMed ID: 38084637
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Matono T; Kuroda H; Yata Y; Ohama H; Tada F; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Yokohama K; Imai M; Koizumi Y; Nakamura S; Iijima H; Kaibori M; Hiasa Y; ;
Oncology; 2023; 101(10):624-633. PubMed ID: 37307798
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients.
Chen YH; Chen YY; Wang JH; Hung CH
Anticancer Res; 2023 Mar; 43(3):1377-1384. PubMed ID: 36854513
[TBL] [Abstract][Full Text] [Related]
6. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Kudo M;
Cancer Rep (Hoboken); 2022 Feb; 5(2):e1464. PubMed ID: 34114752
[TBL] [Abstract][Full Text] [Related]
7. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
Rimini M; Rimassa L; Ueshima K; Burgio V; Shigeo S; Tada T; Suda G; Yoo C; Cheon J; Pinato DJ; Lonardi S; Scartozzi M; Iavarone M; Di Costanzo GG; Marra F; Soldà C; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Pressiani T; Nishida N; Iwamoto H; Sakamoto N; Ryoo BY; Chon HJ; Claudia F; Niizeki T; Sho T; Kang B; D'Alessio A; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimur T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Pedica F; De Cobelli F; Ratti F; Aldrighetti L; Kudo M; Cascinu S; Casadei-Gardini A
ESMO Open; 2022 Dec; 7(6):100591. PubMed ID: 36208496
[TBL] [Abstract][Full Text] [Related]
8. Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma.
Su CW; Teng W; Lin PT; Jeng WJ; Chen KA; Hsieh YC; Chen WT; Ho MM; Hsieh CH; Wang CT; Chai PM; Lin CC; Lin CY; Lin SM
Cancer Med; 2023 Mar; 12(6):7077-7089. PubMed ID: 36468578
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies.
Wang BC; Kuang BH; Lin GH
Target Oncol; 2024 Mar; 19(2):203-212. PubMed ID: 38289445
[TBL] [Abstract][Full Text] [Related]
10. Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Lu J; Lin X; Teng H; Zheng Y
J Clin Pharmacol; 2024 Jun; 64(6):643-651. PubMed ID: 38311835
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes of Ramucirumab as Post-treatment Following Atezolizumab/Bevacizumab Combination Therapy in Advanced Hepatocellular Carcinoma.
Kuzuya T; Kawabe N; Hashimoto S; Funasaka K; Nagasaka M; Nakagawa Y; Miyahara R; Shibata T; Takahara T; Kato Y; Sugioka A; Hirooka Y
Anticancer Res; 2022 Apr; 42(4):1905-1910. PubMed ID: 35347009
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Liu J; Yang L; Wei S; Li J; Yi P
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16191-16201. PubMed ID: 37658861
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.
Rimini M; Persano M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Presa J; Salani F; Lonardi S; Piscaglia F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Schirripa M; Montes M; Vivaldi C; Soldà C; Hiraoka A; Sho T; Niizeki T; Nishida N; Steup C; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Burgio V; Scartozzi M; Cascinu S; Casadei-Gardini A
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7565-7577. PubMed ID: 36976353
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis.
Changez MIK; Khan M; Uzair M; Tahir MF; Mohsin M; Hussain AF; Saqib V; Molani MK; Ahmed AH; Khalid S
J Gastrointest Cancer; 2024 Mar; 55(1):467-481. PubMed ID: 38095799
[TBL] [Abstract][Full Text] [Related]
15. Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Aoki T; Kuroda H; Yata Y; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kudo M;
Liver Int; 2024 Jan; 44(1):113-124. PubMed ID: 37789669
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Yano S; Kawaoka T; Yamasaki S; Johira Y; Kosaka M; Shirane Y; Miura R; Amioka K; Naruto K; Yamaoka K; Fujii Y; Uchikawa S; Fujino H; Ono A; Nakahara T; Murakami E; Miki D; Tsuge M; Teraoka Y; Kouno H; Takaki S; Mori N; Tsuji K; Oka S
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001666
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.
Persano M; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Rimassa L; Presa J; Masi G; Yoo C; Lonardi S; Tovoli F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Pressiani T; Kawaguchi T; Montes M; Vivaldi C; Soldà C; Piscaglia F; Hiraoka A; Sho T; Niizeki T; Nishida N; Steup C; Iavarone M; Di Costanzo G; Marra F; Scartozzi M; Tamburini E; Cabibbo G; Foschi FG; Silletta M; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Cammarota A; Burgio V; Cascinu S; Casadei-Gardini A
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5591-5602. PubMed ID: 36509984
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after Atezolizumab/Bevacizumab Failure: A real-world study.
Chon YE; Kim DY; Kim M; Kim BK; Kim SU; Park JY; Ahn SH; Ha Y; Lee JH; Lee KS; Kang B; Kim JS; Chon HJ; Kim DY
Clin Mol Hepatol; 2024 Mar; ():. PubMed ID: 38468561
[TBL] [Abstract][Full Text] [Related]
19. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
Vithayathil M; D'Alessio A; Fulgenzi CAM; Nishida N; Schönlein M; von Felden J; Schulze K; Wege H; Saeed A; Wietharn B; Hildebrand H; Wu L; Ang C; Marron TU; Weinmann A; Galle PR; Bettinger D; Bengsch B; Vogel A; Balcar L; Scheiner B; Lee PC; Huang YH; Amara S; Muzaffar M; Naqash AR; Cammarota A; Zanuso V; Pressiani T; Pinter M; Cortellini A; Kudo M; Rimassa L; Pinato DJ; Sharma R
Hepatol Int; 2023 Aug; 17(4):904-914. PubMed ID: 37005953
[TBL] [Abstract][Full Text] [Related]
20. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF
World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
